Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - lenalidomidum - capsule rigide - lenalidomidum 10.0 mg, amylum pregelificatum, cellulosum microcristallinum, carmellosum natricum conexum, silica colloidalis anhydrica, natrii stearylis fumaras, kapselhülle: e 172 (flavum), titanii dioxidum, e 172 (nigrum), e 132, gelatina, drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula corresp. natrium 1.588 mg. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - lenalidomidum - capsule rigide - lenalidomidum 15.0 mg, amylum pregelificatum, cellulosum microcristallinum, carmellosum natricum conexum, silica colloidalis anhydrica, natrii stearylis fumaras, kapselhülle: titanii dioxidum, gelatina, drucktinte: lacca, e 172 (rubrum), propylenglycolum, simeticonum, pro capsula corresp. natrium 0.986 mg. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - lenalidomidum - capsule rigide - lenalidomidum 20.0 mg, amylum pregelificatum, cellulosum microcristallinum, carmellosum natricum conexum, silica colloidalis anhydrica, natrii stearylis fumaras, kapselhülle: e 172 (flavum), titanii dioxidum, e 132, gelatina, drucktinte: lacca, e 172 (rubrum), propylenglycolum, simeticonum, pro capsula corresp. natrium 1.282 mg. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - lenalidomidum - capsule rigide - lenalidomidum 25.0 mg, amylum pregelificatum, cellulosum microcristallinum, carmellosum natricum conexum, silica colloidalis anhydrica, natrii stearylis fumaras, kapselhülle: titanii dioxidum, gelatina, drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula corresp. natrium 1.579 mg. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - pancreas in polvere - capsule - kapsel: pancreatis pulvis 300 mg corresp. amylasum 18000 u. ph. eur. et lipasum 25000 u. ph. eur. et proteasum 1000 u. ph. eur., macrogolum 4000, hypromellosi phthalas, alcohol cetylicus, triethylis citras, dimeticonum 1000, kapselhülle: gelatina, natrii laurilsulfas corresp. natrium 16.7 µg, e 172 (flavum), e 172 (rubrum), pro capsula. - enzima prodotto - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - pancreas in polvere - capsule - kapsel: pancreatis pulvis 150 mg corresp. amylasum 8000 u. ph. eur. et lipasum 10000 u. ph. eur. et proteasum 600 u. ph. eur., macrogolum 4000, hypromellosi phthalas, alcohol cetylicus, triethylis citras, dimeticonum 1000, kapselhülle: gelatina, natrii laurilsulfas corresp. natrium 9.6 µg, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro capsula. - enzima prodotto - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - pancreas in polvere - capsule - kapsel: pancreatis pulvis 300 mg, lipasum 20000 u. ph. eur. amylasum 16000 u. ph. eur. proteasum 1200 u. ph. eur. macrogolum 4000, hypromellosi phthalas, alcohol cetylicus, triethylis citras, dimeticonum 1000, kapselhülle: gelatina, natrii laurilsulfas corresp. natrium 16.7 µg, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), e 171, pro capsula. - enzima prodotto - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - pancreas in polvere - capsule - kapsel: pancreatis pulvis 420 mg, lipasum 35000 u. ph. eur. amylasum 25200 u. ph. eur. proteasum 1400 u. ph. eur. macrogolum 4000, hypromellosi phthalas, alcohol cetylicus, triethylis citras, dimeticonum 1000, kapselhülle: gelatina, natrii laurilsulfas corresp. natrium 21.5 µg, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), e 171, pro capsula. - enzima prodotto - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

viatris limited - clopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - agenti antitrombotici - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segment elevation infarto miocardico acuto, in combinazione con asa in medicalmente trattati i pazienti eleggibili per la terapia trombolitica. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. per ulteriori informazioni, si prega di fare riferimento alla sezione 5.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

viatris pharma s.r.l. - venlafaxina - venlafaxina